Publications by authors named "Babak Bayat"

Background: With the increase of the dimensionality in flow cytometry data over the past years, there is a growing need to replace or complement traditional manual analysis (i.e. iterative 2D gating) with automated data analysis pipelines.

View Article and Find Full Text PDF

Background: Developing thermostable vaccines is a challenge for pharmaceutical companies due to the inherent instability of biological molecules in aqueous solution. The problem is even more stringent in regions subjected to high temperatures in which protective cold chain is difficult to maintain due to a lack of infrastructure. Here, a simple, cost-effective solution to increase the thermostability of the malaria candidate vaccine RTS,S/AS01 is described.

View Article and Find Full Text PDF

Two HIV-1 subtype C gp120 protein candidates were the selected antigens for several experimental vaccine regimens now under evaluation in HVTN 100 Phase I/II clinical trial aiming to support the start of the HVTN 702 Phase IIb/III trial in southern Africa, which is designed to confirm and extend the partial protection seen against HIV-1 infection in the RV144 Thai trial. Here, we report the comprehensive physicochemical characterization of the gp120 reference materials that are representative of the clinical trial materials. Gp120 proteins were stably expressed in Chinese Hamster Ovary (CHO) cells and subsequently purified and formulated.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness of two vaccine candidates, AdC7-GRN (a chimpanzee adenovirus) and F4/AS01 (a recombinant fusion protein), in generating immune responses against HIV-1 in both macaques and mice.
  • Results indicate that heterologous prime-boost regimens (combining both vaccines) produce stronger and more sustained CD4+ and CD8+ T-cell responses than homologous regimens, particularly in macaques.
  • The combination of these vaccines not only stimulates high-frequency, antigen-specific T-cell responses but also leads to the production of HIV-1-specific antibodies, showing potential for improved HIV-1 control strategies.
View Article and Find Full Text PDF
Article Synopsis
  • Researchers developed a pre-erythrocytic vaccine candidate targeting the Plasmodium vivax circumsporozoite protein, creating two versions: a soluble protein (VMP001) and a particulate antigen (CSV-S,S) made using yeast.
  • Both vaccine types were tested in rhesus monkeys, showing they could elicit immune responses, but the CSV-S,S version generated higher antibody levels specific to the target protein.
  • The study found differences in immune cell responses based on the vaccine format, suggesting the need for more clinical trials to further evaluate the effectiveness of each type in providing immunity against malaria.
View Article and Find Full Text PDF

Protection against Plasmodium falciparum sporozoite infection can be achieved by vaccination with the recombinant circumsporozoite protein-based vaccine RTS,S formulated with the AS02A Adjuvant System. Since this protection is only partial and wanes over time, we have developed a new RTS,S-based vaccine adjuvanted with AS01B. RTS,S/AS01B-induced high specific antibody titers and increased the frequency of mouse CD4(+) and CD8(+) T cells expressing IFN-gamma, and of monkey CD4(+) T cells expressing IL-2 and/or IFN-gamma and/or TNF-alpha upon stimulation with vaccine antigens.

View Article and Find Full Text PDF

Introduction: Serum prostate-specific antigen (PSA) is still the simplest marker for early diagnosis and follow-up of prostate cancer. Because racial differences in PSA levels have been found, we performed this study to determine the reference level of serum PSA for men in Yasuj, in southwest Iran.

Materials And Methods: Men aged 40 years and older who had been referred to any of the Yasuj hospitals for a blood cell count for any reason were randomly selected.

View Article and Find Full Text PDF

The RTS,S/AS02A protein-based vaccine consistently demonstrates significant protection against infection with Plasmodium falciparum malaria and also against clinical malaria and severe disease in children in areas of endemicity. Here we demonstrate with rhesus macaques that priming with a replication-defective human adenovirus serotype 35 (Ad35) vector encoding circumsporozoite protein (CS) (Ad35.CS), followed by boosting with RTS,S in an improved MPL- and QS21-based adjuvant formulation, AS01B, maintains antibody responses and dramatically increases levels of T cells producing gamma interferon and other Th1 cytokines in response to CS peptides.

View Article and Find Full Text PDF